Latest Breaking News On - Orphan disease summit - Page 1 : comparemela.com

Published: May 21, 2021 BOSTON, May 21, 2021 (GLOBE NEWSWIRE) Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Greg Korbel, Senior Vice President and Chief Business Officer, will present a corporate update at the 2021 Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 3:45 p.m. ET. A webcast of the presentation can be accessed from the “Events Calendar” in the News and Events section of the Aprea website at Link. About Aprea Therapeutics, Inc. Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead product candidate is eprenetapopt (APR-246), a small molecule in cli

United statesGregorya korbelGreg korbelScottm coianteExchange commissionEuropean medicines agencyEuropean commissionSecurities exchangeAprea therapeutics incSenior vice presidentChief business officerOrphan disease summitAprea therapeuticsBreakthrough therapyOrphan drugFast track